OliX Pharmaceuticals prepares for their COVID-19 drug candidate to enter clinical trials

Korean biotechnology and pharmaceutical company, OliX Pharmaceuticals Inc., is preparing to start clinical trials for their COVID-19 drug candidate. Once the drug passes tests against live SARS-CoV-2 (the virus which causes COVID-19), it will enter the clinic after only three months of development. Due to the drug’s design, it could also target the coronaviruses which are responsible for Middle East respiratory syndrome (MERS) and Severe Acute respiratory syndrome (SARS).

Lee Dong-ki, CEO of OliX, said the company has “sufficient funding to support the development of several key pipelines, but more funds will be needed as the number of candidates in the pipeline increases.” As such, OliX will consider partnering with international pharmaceutical companies and financial investors.

Click here to read more.

AKBC Membership

AKBC welcomes new members from both the Australian and Korean business community.

Join now

What’s on

AKBC runs events on a regular basis to keep members informed about the latest developments in Australia-Korea trade and investment.

See events

AKBC Newsletter

AKBC issues a monthly newsletter about the latest trends and developments in the Australia-Korea relationship. Sign up to our free e-newsletter by entering your email below.

Australia Korea Business Council
PO Box 24430
Melbourne, Vic 3001 Australia
Liz Griffin – Executive Director

The Australia-Korea Business Council is the leading national body committed to strengthening the Australia-Korea economic relationship.